Lung cancer risk in relation to mephenytoin hydroxylation activity

被引：14

作者：

Benhamou, S

Bouchardy, C

Dayer, P

机构：

[1] GENEVA CANC REGISTRY,CH-1205 GENEVA,SWITZERLAND

[2] UNIV HOSP GENEVA,DIV CLIN PHARMACOL,CH-1211 GENEVA,SWITZERLAND

来源：

PHARMACOGENETICS | 1997年 / 7卷 / 02期

关键词：

lung cancer; CYP2C19 activity smoking; epidemiology;

D O I：

10.1097/00008571-199704000-00011

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：157 / 159

页数：3

共 11 条

[1]

[Anonymous], 1986, IARC MON EV CARC RIS

[2]

AYESH R, 1985, MICROSOMES DRUG OXID, P340

[3]

Benhamou S, 1996, CANCER EPIDEM BIOMAR, V5, P683

[4]

Bouchardy C, 1996, CANCER RES, V56, P251

[5]

Breslow N.E., 1980, STAT METHODS CANC RE, P192

[6] Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole [J].

Caraco, Y ;

Wilkinson, GR ;

Wood, AJJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (04) :396-404

[7] RAPID SCREENING FOR POLYMORPHISMS IN DEXTROMETHORPHAN AND MEPHENYTOIN METABOLISM [J].

GUTTENDORF, RJ ;

BRITTO, M ;

BLOUIN, RA ;

FOSTER, TS ;

JOHN, W ;

PITTMAN, KA ;

WEDLUND, PJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (04) :373-380

[8] PHENOTYPING POLYMORPHIC DRUG-METABOLISM IN THE FRENCH CAUCASIAN POPULATION [J].

JACQZ, E ;

DULAC, H ;

MATHIEU, H .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (02) :167-171

[9]

KAISARY A, 1987, CANCER RES, V47, P5488

[10] MEPHENYTOIN HYDROXYLATION POLYMORPHISM - CHARACTERIZATION OF THE ENZYMATIC DEFICIENCY IN LIVER-MICROSOMES OF POOR METABOLIZERS PHENOTYPED INVIVO [J].

MEIER, UT ;

DAYER, P ;

MALE, PJ ;

KRONBACH, T ;

MEYER, UA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (05) :488-494

← 1 2 →